The Use of a Virtual Reality Intervention on Stigma, Empathy and Attitudes Towards People With Psychotic Disorders

Sponsor
Institute of Mental Health, Singapore (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05982548
Collaborator
(none)
180
1
2
11.5
15.6

Study Details

Study Description

Brief Summary

The goal of this clinical trial is to evaluate the effectiveness of a VR intervention on (1) stigma, (2) empathy and (3) attitudes towards those experiencing mental disorders.

Participants will review a VR intervention, and complete questionnaires at pre-test, post-test and one month follow-up.

Researchers will compare the VR intervention with a control VR intervention to evaluate the varying effects on stigma, empathy and attitudes towards those experiencing mental disorders.

Condition or Disease Intervention/Treatment Phase
  • Other: VR intervention
  • Other: VR control intervention
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
180 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Primary Purpose:
Other
Official Title:
The Use of a Virtual Reality Intervention on Stigma, Empathy and Attitudes Towards People With Psychotic Disorders Among Mental Healthcare Professionals
Anticipated Study Start Date :
Aug 1, 2023
Anticipated Primary Completion Date :
Jul 17, 2024
Anticipated Study Completion Date :
Jul 17, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Intervention group

The VR intervention was created using the Unreal Engine software (Unreal Engine, 2022). The VR intervention includes the scenario of a home. Participants will view the home as a first person character and experience psychotic phenomena including auditory hallucinations. The intervention will be delivered in one setting and lasts no more than seven minutes. It will be disseminated using smartphone inserted into VR headset equivalent of google cardboard.

Other: VR intervention
VR intervention of no more than 7 minutes Participants viewed the home as a first person character and experience psychotic phenomena including auditory hallucinations.

Active Comparator: VR control group

The VR control group will view the scenario of the same home without the simulated visual and auditory hallucinations.

Other: VR control intervention
VR intervention of no more than 7 minutes Participants viewed the same home as a first person character without psychotic phenomena

Outcome Measures

Primary Outcome Measures

  1. Desire for Social Distance [pre-intervention, immediately after the intervention, follow-up at 1 month after intervention]

    Desire for Social Distance Scale The eight questions are rated on a four-point Likert scale: yes, definitely (0), yes, probably (1), probably not (2) and definitely not (3) with greater scores implying greater desire for social distancing.

  2. Personal Stigma [pre-intervention, immediately after the intervention, follow-up at 1 month after intervention]

    Personal Stigma Scale Personal Stigma Scale consisted of two subscales: 'Personal unpredictable/ dangerousness' and 'Personal weak not sick' The questions were calculated as 'strongly agree' (4) to 'strongly disagree' (0), with greater scores implying greater stigmatizing attitudes.

  3. Empathy [pre-intervention, immediately after the intervention, follow-up at 1 month after intervention]

    Empathetic concern sub-scale of Interpersonal Reactivity Index The 7-item sub-scale is measured on a five point likert scale ranging from 'does not describe me well' (0) to 'describes me very well' (4).

  4. Attitudes towards those experiencing mental disorders [pre-intervention, immediately after the intervention, follow-up at 1 month after intervention]

    modified Attitudes Towards People with Schizophrenia scale The 7-item scale is measured on a nine point likert scale ranging from (1) to (9). Greater scores equate better attitude towards people with schizophrenia.

Secondary Outcome Measures

  1. Demographic data [pre-intervention]

    occupation, gender, marital status, ethnic groups, age, years of service

  2. Acceptability of the intervention [immediately after the intervention]

    Authors constructed questionnaire to assess for acceptability of intervention. A total of 10 questions consisting of 6 multiple choice questions ranging from strongly disagree to strongly agree on a 7-point likert scale. An example of one question is, 'I find the intervention engaging'. It also consists of 4 open ended questions. Example of one question is, 'Please list the strength of the intervention'

  3. Safety of VR intervention [immediately after the intervention]

    Visually induced motion sickness susceptibility questionnaire: It consists of six questions that evaluates presence of adverse effects from using the VR intervention from 'never' (0) to 'often' (3).

Eligibility Criteria

Criteria

Ages Eligible for Study:
21 Years to 99 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Participants who are aged at least 21 years old

  • Employed by the Institute of Mental Health as a physician, allied health professional or nurse.

  • understands English

  • work directly with patients.

Exclusion Criteria:
  • unable to use virtual reality interventions due to reasons including motion sickness, disorientation, nausea and vomiting.

  • history of epilepsy

Contacts and Locations

Locations

Site City State Country Postal Code
1 Institute of Mental Health Singapore Singapore 539747

Sponsors and Collaborators

  • Institute of Mental Health, Singapore

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Tay Jing Ling, Advanced Practice Nurse, Institute of Mental Health, Singapore
ClinicalTrials.gov Identifier:
NCT05982548
Other Study ID Numbers:
  • 2023/00027
First Posted:
Aug 8, 2023
Last Update Posted:
Aug 8, 2023
Last Verified:
Aug 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 8, 2023